A clinical case of the combined acute promyelocytic leukemia and juvenile idiopathic arthritis

The article presents a clinical case of enteritis-associated juvenile idiopathic arthritis in a 16-year-old teenager during the therapeutic stage of consolidation of acute promyelocytic leukemia. Arthritis in a patient with leukemia is usually associated either with an exacerbation of the underlying disease; or with an infectious process in the joint or adjacent bone. Leukemic arthritis is manifested mainly by monoarthritis, with damage to large joints, severe night pain, lymphadenopathy, and hepatosplenomegaly. A reduction in joint pain is a sign of a clinical response to chemotherapy. An infectious lesion of the musculoskeletal system is usually also represented by a local inflammatory process with fever, intoxication, local hyperemia, hyperthermia, inflammatory changes in blood tests and requires intensive antibacterial therapy and temporary cessation of chemotherapy in an oncological patient. The development of juvenile idiopathic arthritis during leukemia therapy caused diagnostic and therapeutic difficulties due to the very rare association of the two diseases, which required the exclusion of a recurrence of leukemia and an infectious complication. NSAID therapy brought temporary relief, the use of the janus kinase blocker upadacitinib was ineffective, and subsequent switching to etanercept allowed for remission of arthritis. Leukemia treatment was carried out in conjunction with JIA treatment.

1. Kostik M.M., Isupova E.A., Shilova E.A., Avrusin I.S., et al. Differential diagnosis of systemic-onset juvenile arthritis and rheumatic masks of oncohematological diseases: a retrospective cohort study. Current Pediatrics. 2017; 16(3): 220 – 225. DOI: 10.15690/i3.1732

2. Boeskorova S.G., Afonskaya M.V., Argunova V.M., et al. Clinical and epidemiological characteristics of juvenile idiopathic arthritis in children of the Republic of Sakha (Yakutia). Pediatrics. 2024; 103(5): 28-37. https://www.elibrary.ru/item.asp?id=73160032

3. Samochatova E.V., et al. Efficiency of acute promyelocytic leukemia treatment with all-transretinoic acid cytosine arabinoside and reduced anthracycline doses. Oncohematology.2008;3:8-17. DOI: 10.17650/1818-8346-20200-3-8-17.

4. Chen X., et al. A novel NPM1-RARG-NPM1 chimeric fusion in acute myeloid leukaemia resembling acute promyelocytic leukaemia but resistant to all-trans retinoic acid and arsenic tri-oxide. Br. J. Cancer. 2019; 120(11): 1023-1025. DOI: 10.1038/s41416-019-0456-z.

5. Akoz A.G., Engin H., Oztoprak N. Atypical presentation of retinoic acid syndrome that mimics septic arthritis in a patient with acute promyelocytic leukemia. Acta Oncol. 2007; 46(8):1193-1194. doi:10.1080/02841860701348688

6. Zhang, Y., Luo, Y., Shi, J., et al. All-trans retinoic acid alleviates collagen-induced arthritis and promotes intestinal homeostasis. Sci Rep 14, 1811 (2024). https://doi.org/10.1038/s41598-024-52322-x

7. Ammatuna E., Huls G. Multidimensional radar dot-plots, do we need it for the screening of acute promyelocytic leukemia? Ann. Hemotol. 2019; 98(7): 1793-1794. DOI: 10.1007/s00277-019-03693-z.

8. Childhood Acute Myeloid Leukemia Treatment (PDQ): Health Professional Version. PDQ Pediatric Treatment Editorial Board. PDQ Cancer Information Summaries [Internet]. National Cancer Institute (US); Bethesda (MD). 6. 2025. PMID: 26389454.

9. Cingam S.R., Koshy N.V. Acute Promyelocytic Leukemia. 2023. Jan.26. In: StаtPearls [Internet]. Treasure Island: StatPearls Publishing; 2025 Jan. PMID: 29083825.

10. Avrusin I.S., Bregel L.V., Efremova O.S., et al. Development of preliminary criteria of macrophage activation syndrome in multisystem inflammatory syndrome associated with COVID-19 in children. Biomedicines. 2024;12(12):2868. doi:10.3390/biomedicines12122868.

11. Alfonso R., et al. Differences between leukemic arthritis and juvenile idiopatic arthritis. Pediatric Rheumatology. 2023; 21(50). DOI: 10.1186/s12969-023-00836-5.

12. Huang Q., Zhang Y., Zheng M. Clinical analysis of 82 cases of acute promyelocytic leukemia with PML-RARa short isoform in children and adults. J. Front Oncol. 2024; 21(14). DOI: 10.3389/fonc.2024.1342671.

13. Gasparovic L., Weiler S., Higi L., et al. Incidence of Differentiation Syndrome Associated with Treatment Regimens in Acute Myeloid Leukemia: A Systematic Review of the Literature. J Clin Med. 2020;9(10):3342. doi:10.3390/jcm9103342

14. Saper V.E., Tian L., Verstegen R.H.J. et al. Interleukin (IL)-1/IL-6-Inhibitor-Associated Drug Reaction With Eosinophilia and Systemic Symptoms (DReSS) in Systemic Inflammatory Illnesses. J Allergy Clin Immunol Pract. 2024;12(11):2996-3013.e7. doi:10.1016/j.jaip.2024.07.002

15. Yilmaz Tasdelen O., Yurdakul F.G., et al. Isotretinoin-induced arthritis mimicking both rheumatoid arthritis and axial spondyloarthritis. Int J Rheum Dis. 2015;18(4):466-469. doi:10.1111/1756-185X.12464

16. Zhang X., et al. MLL-rearrangement can resemble acute promyelocytic leukemia. Leuk Lymphoma. 2019; 60(11). 2841-2843. DOI: 10.1080/10428194.2019.1607328.

17. Elnady B., Elkhouly T., Dawoud N.M. New onset of axial spondyloarthropathy in patients treated with isotretinoin for acne vulgaris: incidence, follow-up, and MRI findings. Clin Rheumatol. 2022; 41(8):2615. doi: 10.1007/s10067022-06178-z

18. Rajani P.Y., et al. Outcomes in adult acute promyelocytic leukomia: a decade experience. J. CLML. 2020; 20(4):158-164. DOI: 10.1016.2019.12.011.

19. Louvigné M., et al. Persistent osteoarticular pain in children: early clinical and laboratory findings suggestive of acute lymphoblastic leukemia (a multicenter case-control study of 147 patients). Pediatr Rheumatol Online J. 2020;18(1):1. doi: https://doi.org/10.1186/s12969-019-0376-8.

20. Yan W., et al. RNF8 is responsible for ATRA resistance in in variant acute promyelocytic leukemia with GTF21/RARA fusion, and inhibition of the ubiquitin-proteasome pathway contributes to the reversion of ATRA resistance. Cancer Cell. Int. 2019; 19: 84. DOI: 10.1186/s12935-019-0803-4.

21. Fonseca M.B., et al. Signs and symptoms of rheumatic diseases as first manifestation of pediatric cancer: diagnosis and prognosis implications. J. Rev. Bras. Reumatol. 2017; 57:330. 7. doi: 10.1016/j.rbre.2017.01.007ммм